LAPACT: An open-label, multicenter phase II trial of <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (Gem) in patients (pts) with locally advanced pancreatic cancer (LAPC).

Philip Agop Philip, Pascal Hammel, Scot Dowden et al.|Journal of Clinical Oncology|2016

Cited by 3